
UNIFLEX – N Cream
Therapeutic Class
Antibacterial agent with Corticosteriods
Indications
Unlflex –N Cream is indicated for the relief of corticosteroid-responsive Inflammatory dermatoses, especially when secondary .bacterial infection is present or likely to be present. It is Indicated for the treatment of eczema, psoriasis,lichen planus, seborrheic dermatitis,intertrigo, contact sensitiVIty reactions,d1sco1d lupus erythematosus, generalized erythroderma. Unlftex-N can be used for the relief of Insect bites and stings.
Chemical Composition
Betamethasone 0.1 % w/w & Neomycin 0.5% w/w
Packaging
15 g / Tube
Dosage & Administration
For external use only. Apply a thin film of Unlflex-N Cream to the affected areas one to three times a day until improvement occurs. It is often effective to maintain improvement by just two or fewer applications a day.
Contraindications
Uniftex-N Cream should not be used for acne, rosacea or on areas around the mouth; viral infections such as herpes simplex (cold sore), chicken pox;fungal or bacterial
Warning & Precautions
If irritation develops with the use of Uniflex-N, treatment should be discontinued and appropriate therapy instituted. Prolonged topical therapy should be avoided where possible. Any of the side effects reported following systemic use of corticosteroids including adrenal suppression, may also occur following their topical use, especially in children and infants. Systemic absorption will be increased if extensive body surfaces are treated orif occlusive dressing is used.
Side Effects
Uniftex-N is usually well tolerated, but adverse reactions like irritation, dryness,allergic contact dermat itis, blurred vision may sometimes occur. If hypersensitivity occurs, treatment should be discontinued immediately.
Drug Interaction
Topical application of Uniftex-N is not likely to produce significant drug interactions. Systemically, neomycin may enhance the anticoagulant effects of warfarin and nicoumalone. lts ototoxicity may be increased by ethacrynic acid and frusemide.Concurrent use of barbiturates, phenytoin,or rifampicin may enhance the metabolism and decrease the effect of corticosteroids In laboratory animals, topical administration of steroids has been associated with foetaldeformities. Therefore, corticosteroid should not be used in large amounts or for prolonged periods in pregnant women. Visual disturbance may be reported with systemic and topical corticosteroid use. lf a patient presents with symptoms suchas blurred visionor other visual disturbances,the patient should be considered for referral to an ophthalmologist for evaluat Ion of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topicalcorticosteroids.